Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13646378 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL330190 | 1.00 | — | — | |
| SCHEMBL14306984 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| Cyclohexane SCHEMBL7799464 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13825653 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20903 | 1.00 | — | — | |
| Cyclopentane SCHEMBL9063672 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16260127 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4986081 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13973760 | 1.00 | ESR1 (0.40) | ESR1ESR2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391597-B1 | METHOD FOR PRODUCING PURE CYCLODODECANONE | BASF SE (DE) | 2018-08-22 | — | — | EP | disclosed |
| EP-2041061-B1 | Purification of cyclododecanon via thermic treatment | BASF SE (DE) | 2013-05-08 | — | — | EP | disclosed |
| US-8188320-B2 | Process for preparing pure cyclododecanone | BASF SE (DE) | 2012-05-29 | — | — | US | disclosed |
| EP-2038245-B1 | METHOD FOR PURIFYING CYCLIC KETONES | BASF SE (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010115869-A1 | PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS | SEPS PHARMA N.V. (BE) | 2010-10-14 | — | — | WO | disclosed |
| US-7790930-B2 | Method for purifying cyclic ketones | BASF SE (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20100191018-A1 | PROCESS FOR PREPARING PURE CYCLODODECANONE | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
| US-7714171-B2 | Method for purifying cyclic ketones | BASF SE (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090326277-A1 | METHOD FOR PURIFYING CYCLIC KETONES | BASF SE (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090318733-A1 | METHOD FOR PURIFYING CYCLIC KETONES | BASF SE (DE) | 2009-12-24 | — | — | US | disclosed |
| US-5635302-A | CURED COATING COMPRISING STERICALLY HINDERED MONOMER AND ETHYLENICALLY UNSATURATED COMONOMER | BASF CORPORATION (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0073042-B1 | POLYESTER COMPOSITION | ETHYL CORPORATION (US) | 1987-10-07 | — | — | EP | disclosed |
| US-4539352-A | POLYETHYLENE TEREPHTHALATE WITH EPOXIDIZED PLASTICIZER AND NUCLEATION AGENT | ETHYL CORPORATION (US) | 1985-09-03 | — | — | US | disclosed |
| EP-0046961-B1 | EPOXY-CYCLOALKYLALKANECARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4486561-A | EPOXIDIZED ESTER AND NUCLEATING AGENT | ETHYL CORPORATION (US) | 1984-12-04 | — | — | US | disclosed |
| US-4430339-A | PROPHYLAXIS, METABOLISM, GLUCOSE, FATS, HYPOGLYCEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-02-07 | — | — | US | disclosed |
| EP-0073042-A1 | Polyester composition | ETHYL CORPORATION (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0046961-A1 | Epoxy-cycloalkylalkanecarboxylic acids, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-10 | — | — | EP | disclosed |
| US-4017505-A | FUNGICIDES, ANTHELMINTICS | MERCK & CO., INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-3936479-A | 2-BENZAMIDO-BENZOPHENONES, UV STABILIZERS, PLASTICS | SANDOZ LTD., (SANDOZ AG) (CH) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191018-A1 | PROCESS FOR PREPARING PURE CYCLODODECANONE | CCNA1, CYC1, CCNA2 | ESR1 2905/4885ESR2 1405/4885CYP3A4 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.